BIOAGE LABS, INC. Research and Development Expense
BIOAGE LABS, INC. (BIOA) reported Research and Development Expense of $24.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- BIOAGE LABS, INC. research and development expense for the quarter ending 2026-06-30 was $24.36M, a 22.78% increase year-over-year.
- BIOAGE LABS, INC. research and development expense for the quarter ending 2026-03-31 was $20.41M, a 83.72% increase year-over-year.
- BIOAGE LABS, INC. research and development expense for the quarter ending 2025-12-31 was $24.50M, a 27.44% increase year-over-year.
- BIOAGE LABS, INC. research and development expense for the quarter ending 2025-09-30 was $18.51M, a 7.52% decline year-over-year.
- BIOAGE LABS, INC. research and development expense for fiscal 2025 was $73.97M, a 25.29% increase from fiscal 2024.
- BIOAGE LABS, INC. research and development expense for fiscal 2024 was $59.04M, a 74.22% increase from fiscal 2023.
- BIOAGE LABS, INC. research and development expense for fiscal 2023 was $33.89M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.36M 10-Q · filed 2026-08-05 | $44.77M 10-Q · filed 2026-08-05 | $69.28M derived: sum of 3 quarters · filed 2026-08-05 | $87.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $20.41M 10-Q · filed 2026-05-08 | $44.91M derived: sum of 2 quarters · filed 2026-05-08 | $63.42M derived: sum of 3 quarters · filed 2026-05-08 | $83.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $24.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $43.01M derived: sum of 2 quarters · filed 2026-03-24 | $62.86M derived: sum of 3 quarters · filed 2026-08-05 | $73.97M 10-K · filed 2026-03-24 |
| 2025-09-30 | $18.51M 10-Q · filed 2025-11-06 | $38.36M derived: sum of 2 quarters · filed 2026-08-05 | $49.47M 10-Q · filed 2025-11-06 | $68.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $19.84M 10-Q · filed 2026-08-05 | $30.95M 10-Q · filed 2026-08-05 | $50.18M derived: sum of 3 quarters · filed 2026-08-05 | $70.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $11.11M 10-Q · filed 2026-05-08 | $30.33M derived: sum of 2 quarters · filed 2026-05-08 | $50.35M derived: sum of 3 quarters · filed 2026-05-08 | $60.82M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $19.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $39.24M derived: sum of 2 quarters · filed 2026-03-24 | $49.72M derived: sum of 3 quarters · filed 2026-03-24 | $59.04M 10-K · filed 2026-03-24 |
| 2024-09-30 | $20.02M 10-Q · filed 2025-11-06 | $30.49M derived: sum of 2 quarters · filed 2025-11-06 | $39.81M 10-Q · filed 2025-11-06 | $49.89M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $10.47M 10-Q · filed 2025-08-06 | $19.79M 10-Q · filed 2025-08-06 | $29.87M derived: sum of 3 quarters · filed 2025-08-06 | $36.41M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $9.32M 10-Q · filed 2025-05-06 | $19.40M derived: sum of 2 quarters · filed 2025-05-06 | $25.93M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $10.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $16.61M derived: sum of 2 quarters · filed 2025-03-20 | $33.89M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $6.53M 10-Q · filed 2024-11-07 | $23.80M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |